You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 8 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 8 findings. Do not include any additional text.

Abstract:
ABSTRACT: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label, randomized phase II trial comparing the combination of pentostatin, cyclophosphamide and rituximab (PCR) either without or with bevacizumab (PCR-B) in previously untreated CLL patients. A total of 65 evaluable patients were enrolled, 32 receiving PCR and 33 PCR-B. A higher rate of grade 3-4 cardiovascular toxicity was observed with PCR-B (33% vs. 3%, p < 0.003). Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09). No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab. A significant post-treatment increase in VEGF levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL); in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of CR (p = 0.01). In conclusion, the addition of bevacizumab to chemoimmunotherapy in CLL is generally well-tolerated and appears to prolong PFS and TFS.

Findings:
[["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "post-treatment vascular endothelial growth factor (VEGF) levels", "significantly increased", "A significant post-treatment increase in VEGF levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL);"], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "treatment-free survival (TFS)", "no significant difference", "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09)."], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "treatment-free survival (TFS)", "no significant difference", "No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab."], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "CCL-3 levels with achievement of complete remission (CR)", "significantly decreased", "in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of CR (p = 0.01)."], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "PFS and TFS by IGHV mutational status", "no significant difference", "No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab"], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "complete remission (CR) rate", "no significant difference", "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08),"], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "progression-free survival (PFS)", "no significant difference", "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09)."], ["chemoimmunotherapy with bevacizumab (PCR-B)", "chemoimmunotherapy without bevacizumab (PCR)", "progression-free survival (PFS)", "no significant difference", "In conclusion, the addition of bevacizumab to chemoimmunotherapy in CLL is generally well-tolerated and appears to prolong PFS and TFS."]]